



CIN : L65910MH1992PLC067632

Date: 02/06/2026

To,
BSE Limited
Department of Corporate Services
P. J. Towers,
Dalal Street, Fort,
Mumbai - 400001.
Scrip Code: 511523

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Press Release

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith our Press Release on Audited Financial Results for the Quarter and year ended March 31, 2026.

We request you to kindly take the above on record.

Thanking you,

Yours truly,

For Veerhealth Care limited



Bhavin S. Shah
Managing Director
DIN: 03129574



Veerhealth Care Limited Reports Robust 86.08% YoY growth at ₹ 33.29 Crore in Total Revenues and 82.68% YoY growth at ₹ 3.27 Crore in EBITDA

Mumbai – 1st June, 2026: Veerhealth Care Limited (BSE: VEERHEALTH), Ayuveer, backed by Veerhealth Care's expertise in Ayurveda, specializes in crafting ayurvedic medicines and oral care products with natural ingredients. With a focus on quality and affordability, Ayuveer aims to offer an exceptional and safe daily care experience to its customers.

FY26 Standalone Financial Highlights

- Total Income of ₹ 33.29 Crore, YoY growth of 86.08%
- EBITDA of ₹ 3.27 Crore, YoY growth of 82.68%
- EBITDA Margin of 9.82% YoY decline of 18 BPS
- Net Profit of ₹ 0.54 Crore, YoY growth of 38.46%
- Net Profit Margin of 1.62%, YoY decline of 56 BPS

Note: Q4FY26 Profit was impacted due to Forex Loss of ₹ 0.31 Crore classified as Exceptional items & Provision of ₹ 0.49 Crore for Deferred Tax. In FY27 the company do not expect repeat of such expenses.

➤ **Key Highlights:**

- The India-EU Trade Deal 2026 is transforming the future of Modern Ayurveda exports from India, opening new growth opportunities in the global wellness market. With reduced tariffs, improved regulatory access, and rising European demand for natural healthcare, Indian Ayurvedic products are gaining strong momentum in the European Union.

From Ayurvedic medicines and herbal supplements to organic skincare and wellness tourism, India's traditional healing system is becoming a major contributor to the global herbal products market.

- In line with its "Local to Global" ambition, Veerhealth Care is actively working towards scaling its manufacturing and export operations for products under the medical device category in the U.S. market. Discussions are ongoing with a major Russian group for oral care exports; expected entry into Russian market soon.



➤ **Key Milestones:**

- During FY26 the company has announced following Orders from --
USA Export of ₹1.39 crs.
Domestic market place of ₹3.28 crs.
Domestic chain of Pharmacy of ₹1.76 crs
Leading FMCG company of ₹10.08 crs
- Completed onboarding of Ayuveer products on Myntra, expanding e-commerce presence. Now present across Amazon, Flipkart, Nykaa, Glowroad, Jiomart, and Myntra.
- Commenced production at new facility with in-house plastic molding for packaging and backward integration.

Globally, very few small-cap companies have secured USFDA plant clearance, positioning Veerhealth Care in a distinctive category.

Veerhealth Care Limited specializes in manufacturing of Pure Vegetarian toothpaste.

In F.Y. 2026-27 we are expecting Total Revenues of ₹ 70-75 crores with PAT of 7-10%.

Veerhealth Care is expecting to reach Revenues of ₹ 100 crores with PAT of 10% in next 24 months.

Commenting on the financial performance, Mr. Bhavin Shah - Managing Director of Veerhealth Care Limited, said, "I am delighted with the strides we have made in FY26 by reporting Highest ever Total Revenues of ₹33.29 crore, driven by our consistent focus on expanding our international footprint and strengthening our domestic presence. The growth in our Export Sales and the addition of new product categories have significantly bolstered our position in the global and local markets. As per existing Order Book in hand we expect to maintain the high growth rates which we have delivered in FY26. These achievements are a testament to our strategy and pave the way for sustained growth and value creation in the coming quarters."

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

